Macrogenics (MGNX) Change in Receivables (2012 - 2026)
Macrogenics (MGNX) posted quarterly Change in Receivables of -$2.9 million for Q1 2026, down 147.28% year-over-year from $6.2 million in Q1 2025, and up 94.72% quarter-over-quarter from -$55.9 million in Q4 2025.
Analysis
Macrogenics (MGNX) Change in Receivables (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Change in Receivables for 15 consecutive years, with -$2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 147.28% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$117000.0 (down 103.52% YoY), while the FY2025 annual figure was $9.1 million, up 249.6% from the prior year.
- Change in Receivables advanced to -$2.9 million in Q1 2026 per MGNX's latest filing, from -$55.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at $56.7 million in Q3 2025 and bottomed at -$55.9 million in Q4 2025.
- Historically, Change in Receivables has averaged $2294.1 across 5 years, with a median of -$1.0 million in 2024.
- On a YoY basis, Change in Receivables climbed as much as 2114.77% in 2025 and fell as far as 1157.5% in 2025.
- Macrogenics' Change in Receivables stood at $42.4 million in 2022, then slumped by 135.26% to -$14.9 million in 2023, then jumped by 70.28% to -$4.4 million in 2024, then slumped by 1157.5% to -$55.9 million in 2025, then soared by 94.72% to -$2.9 million in 2026.
- Business Quant data shows MGNX's Change in Receivables at -$2.9 million in Q1 2026, -$55.9 million in Q4 2025, and $56.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | 25.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -55.86 Mn |
| Sep 30, 2025 | 56.70 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 6.23 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -14.94 Mn |
| Sep 30, 2023 | 18.90 Mn |
| Jun 30, 2023 | -29.75 Mn |
| Mar 31, 2023 | -20.06 Mn |
| Dec 31, 2022 | 42.38 Mn |
| Sep 30, 2022 | -4.55 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 4.52 Mn |
| Dec 31, 2021 | -3.37 Mn |
| Sep 30, 2021 | -31.49 Mn |